| HOME >> BIOLOGY >> TECHNOLOGY |
Changes in operating assets and
liabilities, net (17,859) (14,606)
Net cash provided by operating activities 45,860 35,622
Investing activities:
Expenditures for property, plant and
equipment (8,279) (10,902)
Proceeds from sale of fluorescent detection
products business 900 -
Repurchase of sale-leaseback equipment (3,910) (6,877)
Capitalization of intangible assets (6,010) (6,862)
Net cash used in investing activities (17,299) (24,641)
Financing activities:
Repayments of notes payable and other
long-term obligations, net (1,013) (3,009)
Repayments under revolving credit
facility, net (36,000) (19,000)
Proceeds from stock option exercises
and other, net 3,272 4,509
Net cash used in financing activities (33,741) (17,500)
Net change in cash, cash equivalents and
short-term investments (5,180) (6,519)
Cash, cash equivalents and short-term
investments, beginning of period 26,828 33,347
Cash, cash equivalents and short-term
investments, end of period $21,648 $26,828
CONTACT
Kyle Stults
Investor Relations
(410) 740-0081
| SOURCE Martek Biosciences Corporation Copyright©2007 PR Newswire. All rights reserved |